TELA Bio shares rise 20.93% premarket ahead of Q3 2025 earnings report and investor conference call.

TELA Bio surged 20.93% in premarket trading following the announcement of its third-quarter 2025 financial results on November 13, 2025, accompanied by a conference call and webcast. The company also appointed William Plovanic, a healthcare equity research expert with operational leadership experience, to its board. The earnings disclosure likely fueled investor optimism, as the pre-earnings rally suggests anticipation of strong results or strategic updates. The board appointment added credibility, potentially reinforcing confidence in TELA Bio’s future direction. Together, these developments aligned with the stock’s upward movement, reflecting market readiness for positive financial and governance news.